Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Retained Earnings (2016 - 2025)

Avalo Therapeutics (AVTX) has disclosed Retained Earnings for 12 consecutive years, with $41000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Retained Earnings rose 100.01% year-over-year to $41000.0, compared with a TTM value of $41000.0 through Sep 2025, up 100.01%, and an annual FY2024 reading of -$370.3 million, down 10.48% over the prior year.
  • Retained Earnings was $41000.0 for Q3 2025 at Avalo Therapeutics, up from -$404.2 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $41000.0 in Q3 2025 and bottomed at -$456.4 million in Q1 2024.
  • Average Retained Earnings over 5 years is -$301.2 million, with a median of -$313.8 million recorded in 2023.
  • The sharpest move saw Retained Earnings plummeted 53.96% in 2021, then skyrocketed 100.01% in 2025.
  • Year by year, Retained Earnings stood at -$262.2 million in 2021, then decreased by 15.89% to -$303.8 million in 2022, then decreased by 10.31% to -$335.1 million in 2023, then decreased by 10.48% to -$370.3 million in 2024, then skyrocketed by 100.01% to $41000.0 in 2025.
  • Business Quant data shows Retained Earnings for AVTX at $41000.0 in Q3 2025, -$404.2 million in Q2 2025, and -$383.4 million in Q1 2025.